This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Clinical Insider
Clinical Insider

Quanticate teams with machine learning firm PhaseV with an eye on adaptive trials

Posted by on 29 April 2024
Share this article

Quanticate has partnered with AI software firm PhaseV to expand its capabilities in adaptive clinical trials, which it says are an area of growing demand.

The deal – financial terms of which were not provided – will combine Quanticate's data management, biostatistics and statistical programming offering with PhaseV's machine learning (ML) platform for adaptive trials.

The idea is to cater for growth biopharmaceutical industry demand for greater flexibility in drug research, according to Quanticate CEO, David Underwood.

“There is currently a great need in the pharmaceutical industry to leverage flexible, dynamic, and adaptive trial designs based on simulations, Bayesian-statistics, machine learning and accumulation of data throughout a trial while continuing to maintain the highest scientific integrity.

He added "PhaseV's platform allows trial teams to seamlessly evaluate and execute all types of designs. We are pleased to enhance our services and foster drug development innovation through this collaboration."

Adaptive trials as the name implies are studies that can be modified while running based on data accumulated as the research progresses. Advocates say the approach can make studies more efficient – by accelerating time to market, requiring fewer patients and lowering costs.

The downside is that adaptive trials are more complex and potentially have a higher operational burden than more traditional protocols.

Partnering with PhaseV will provide the tools to help sponsors overcome these challenges while reaping the benefits of an adaptive design, tailored to their specific needs and objectives according to Quanticate.

The agreement is in keeping with the plan PhaseV outlined when it completed a $15 million fundraising round last October.

At the time CEO and co-founder Raviv Pryluk, said "This investment provides us with the resources to further advance our platform and expand our reach to additional pharma, CRO and biotech companies in Europe and the US, bringing new needed treatments to patients."


Share this article

Sign up for Clinical Insider email updates